Skip to main content Skip to main navigation menu Skip to site footer

Systematic review: andrographolide as a potential Anti-inflammatory treatment for psoriasis


A chronic inflammatory skin condition called psoriasis affects 1-3% of people worldwide. It will lead to other psychological, endocrine, and cardiovascular issues. It mainly affects the elbows, knees, scalp, back, umbilicus, and lumbar regions and is distinguished by well-defined crimson plaques and thick silvery white scales. Topical corticosteroid cream has been the main therapy in treating inflammatory skin in psoriasis vulgaris until now. Nowadays, andrographolide is an active compound of Andrographis paniculate, or the name in Indonesia is Sambiloto, which has been reported as a potential anti-inflammatory. Therefore, this study aimed to systematically review the published efficacy of andrographolide as an anti-inflammatory in an in vivo study and synthesize the available data. This study was a literature review searched using PubMed/ Medline, Science Direct, and Cochrane up to September 2022. The following search terms were used: (andrographolide or Andrographis paniculate) AND (anti-inflammatory) AND (animal study or in vivo). The bias in the research using the Newcastle-Ottawa quality assessment score was rated as low risk, of some concern, or high risk. A total of six in vivo studies were included in our analysis. Methotrexate and biologic agents are used for the systemic treatment of psoriasis. Topical corticosteroid therapy remains the first line of topical therapy but has some side effects. Specific reporting of andrographolide as a potential anti-inflammatory in other inflammatory diseases is necessary to support the possible treatment for psoriasis. There still needs to be further studies regarding the use of andrographolide as a topical psoriasis treatment.


  1. Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64:66–73.
  2. Huerta C, Rivero E, García Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143(12):1559–65.
  3. Segar D, Praharsini I, Indira IE. Prevalence and clinical manifestations of patients with psoriasis in RSUP Sanglah from 2017 to 2018. Intisari Sains Medis. 2019;10(3):840–4.
  4. Oliveira M de FSP de, Rocha B de O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20.
  5. Maul JT, Anzengruber F, Conrad C, Cozzio A, Häusermann P, Jalili A, et al. Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology. 2021;237(2):166–78.
  6. Kleyn EC, Morsman E, Griffin L, Wu JJ, Cm van de Kerkhof P, Gulliver W, et al. Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments. J Dermatolog Treat. 2019;30(4):311–9.
  7. Warditiani NK, Sari PMNA, Ramona Y, Wirasuta MAG. Molecular pharmacology study of andrographolide extracted from andrographis paniculata on atherosclerosis preventive effect. Syst Rev Pharm. 2020;11(9):201–6.
  8. Parichatikanond W, Suthisisang C, Dhepakson P, Herunsalee A. Study of anti-inflammatory activities of the pure compounds from Andrographis paniculata (burm.f.) Nees and their effects on gene expression. Int Immunopharmacol. 2010;10(11):1361–73.
  9. Abu-Ghefreh AA, Canatan H, Ezeamuzie CI. In vitro and in vivo anti-inflammatory effects of andrographolide. Int Immunopharmacol. 2009;9(3):313–8.
  10. Kumar G, Singh D, Tali JA, Dheer D, Shankar R. Andrographolide: Chemical modification and its effect on biological activities. Bioorg Chem. 2020;95:103511.
  11. Horváth S, Komlódi R, Perkecz A, Pintér E, Gyulai R, Kemény Á. Methodological refinement of Aldara-induced psoriasiform dermatitis model in mice. Sci Rep. 2019;9(1):1–8.
  12. Torsekar R, Gautam M. Topical therapies in psoriasis. Indian Dermatol Online J. 2017;8(4):235.
  13. Ahmed S, Kwatra M, Panda SR, Murty USN, Naidu VGM. Andrographolide suppresses NLRP3 inflammasome activation in microglia through induction of Parkin-mediated Mitophagy in in-vitro and in-vivo models of Parkinson disease. Brain Behav Immun. 2020; 91:142-158. doi:
  14. Gupta S, Mishra KP, Kumar B, Singh SB, Ganju L. Andrographolide attenuates complete freund’s adjuvant induced arthritis via suppression of inflammatory mediators and pro-inflammatory cytokines. J Ethnopharmacol. 2020;113022.
  15. Li F, Li H, Luo S, Ran Y, Xie X, Wang Y, et al. Biomedicine & Pharmacotherapy Evaluation of the e ff ect of andrographolide and methotrexate combined therapy in complete Freund ʼ s adjuvant induced arthritis with reduced hepatotoxicity. 2018;106(May):637–45.
  16. Shu J, Huang R, Tian Y, Liu Y, Zhu R, Shi G. Andrographolide protects against endothelial dysfunction and inflammatory response in rats with coronary heart disease by regulating PPAR and NF- κ B signaling pathways. 2020;(2):1–11.
  17. Gao J, Cui J, Zhong H, Li Y, Liu W, Jiao C, et al. Andrographolide sulfonate ameliorates chronic colitis induced by TNBS in mice via decreasing inflammation and fibrosis. Int Immunopharmacol. 2020;83:106426.
  18. Shao F, Tan T, Tan Y, Sun Y, Wu X, Xu Q. Andrographolide alleviates imiquimod-induced psoriasis in mice via inducing autophagic proteolysis of MyD88. Biochem Pharmacol. 2016;115:94–103.
  19. Jindal S, Awasthi R, Singare D, Kulkarni GT. Isolation, characterization and evaluation of anti-proliferative properties of andrographolide isolated from Andrographis paniculata on cultured HaCaT cells. Herba Pol. 2021;67(1):35–45.
  20. Agust R, Alarc P, Quiroga J, Manosalva C, Hancke J. All Roads Lead to Cellular Metabolism. Molecules. 2021;26(5):1–17.
  21. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA - J Am Med Assoc. 2020;323(19):1945–60.
  22. Reid C, Griffiths CEM. Psoriasis and treatment: Past, present and future aspects. Acta Derm Venereol. 2020;100(100-year theme Psoriasis):69–79.
  23. Chuerduangphui J, Nukpook T, Pientong C, Aromdee C, Suebsasana S, Khunkitti W, et al. Activity of 3,19-isopropylidinyl andrographolide against herpes simplex virus type 1 in an animal model. Antivir Chem Chemother. 2022;30:1–7.
  24. Dermatology I. Adverse Effects of Long-Term Oral Corticosteroids in the Department of Dermatology , Antananarivo ,. 2021;1337–41.
  25. Dolz-Pérez I, Sallam MA, Masiá E, Morelló-Bolumar D, Pérez del Caz MD, Graff P, et al. Polypeptide-corticosteroid conjugates as a topical treatment approach to psoriasis. J Control Release. 2020;318:210–22.

How to Cite

Dharmasamitha, I., Warditiani, N. K., Rusyati, L. M., Wati, D., & Gelgel Wirasuta, M. A. (2023). Systematic review: andrographolide as a potential Anti-inflammatory treatment for psoriasis. Bali Medical Journal, 12(1), 1187–1192.




Search Panel

Indira Dharmasamitha
Google Scholar
BMJ Journal

Ni Kadek Warditiani
Google Scholar
BMJ Journal

Luh Mas Rusyati
Google Scholar
BMJ Journal

DK Wati
Google Scholar
BMJ Journal

Made Agus Gelgel Wirasuta
Google Scholar
BMJ Journal